Showing 5331-5340 of 9401 results for "".
- Three Dermal Filler Patients Had Adverse Reactions to the Moderna COVID-19 Vaccinehttps://practicaldermatology.com/news/three-filler-patients-had-adverse-reactions-to-the-moderna-covid-19-vaccine/2460642/Three patients with dermal fillers have had adverse reactions to the Moderna COVID-19 vaccine, according to the Aesthetic Society. The FDA intends to note this in its prescribing information. There have been no reported cases in patients receiving the Pfizer COVID-19 vaccine.
- Ajinomoto Bio-Pharma Services and Revance Therapeutics Announce Manufacturing Agreement for Supply of DaxibotulinumtoxinA for Injectionhttps://practicaldermatology.com/news/ajinomoto-bio-pharma-services-and-revance-therapeutics-announce-manufacturing-agreement-for-supply-of-daxibotulinumtoxina-for-injection/2460641/Ajinomoto Bio-Pharma Services will serve as a supply source and provide manufacturing for Revance Therapeutics, Inc.’s DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection is currently under Biologics License Application (BLA) review.
- DermOQ Oxygen Lab Completes Purchase of ECHO2 Plus Oxygen Facial Treatment Product Line from Skin Products, Inc.https://practicaldermatology.com/news/dermoq-oxygen-lab-completes-purchase-of-echo2-plus-oxygen-facial-treatment-product-line-from-skin-products-inc/2460640/DermOQ Oxygen Lab closed their acquisition of ECHO2 Plus Oxyceuticals oxygen facial treatment product line from Skin Products, Inc. for an undisclosed amount. "ECHO2 Plus is a 45-minute facial treatment offered at physician's offices, spas, hotels and corporate custom
- For Upper Facial Lines, DaxibotulinumtoxinA Succeeds in Phase 2https://practicaldermatology.com/news/for-upper-facial-lines-daxibotulinumtoxina-succeeds-in-phase-2/2460637/Topline efficacy and safety results from the phase 2 multicenter, open-label study of Revance's investigational drug candidate DaxibotulinumtoxinA for Injection for the combined treatment of upper facial lines, show high levels of patient satisfaction. The 36-week study enrolled 48
- LEO Pharma Taps Jörg Möller as EVP, Global Research and Developmenthttps://practicaldermatology.com/news/leo-pharma-taps-jorg-moller-as-evp-global-research-and-development/2460636/Jörg Möller is joining LEO Pharma A/S’s Global Leadership Team as Executive Vice President (EVP), Global Research and Development, effective January 1, 2021. Möller joins LEO Pharma from Bayer Pharma, where he has been EVP Head of R&D and Member of the Bayer Pha
- Hydrafacial To Go Public After $1.1 Billion Dealhttps://practicaldermatology.com/news/hydrafacial-to-go-public-after-11-billion-deal/2460634/The HydraFacialCompany and Vesper Healthcare, a special purpose acquisition company (SPAC) co-founded by Brent Saunders, former CEO of Allergan, have entered into a definitive merger agreement. Under the terms of the agreement, HydraFacial and Vesper Healthcare will combine, and HydraFa
- Positive Topline Data from Phase 2b Study of Roflumilast Foam for Scalp and Body Psoriasishttps://practicaldermatology.com/news/positive-topline-data-from-phase-2b-study-of-roflumilast-foam-for-scalp-and-body-psoriasis/2460633/Arcutis Biotherapeutics, Inc., a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, shared positive top line data from a Phase 2b clinical trial evaluating ARQ-
- Evelo's AD Candidate Meets Phase 1b Endpointshttps://practicaldermatology.com/news/evelos-ad-candidate-meets-phase-1b-endpoints/2460631/Evelo Biosciences, Inc.’s investigational atopic dermatitis treatment EDP1815 was well tolerated with no serious adverse events in a phase 1b clinical trial. According to the company, the oral drug candidate studied in 23 evaluable subjects with
- AbbVie’s Rinvoq Performs Well in Head-to-Head Phase 3b AD Studyhttps://practicaldermatology.com/news/abbvies-rinvoq-performs-well-in-head-to-head-phase3b-ad-study/2460630/Topline results from the phase 3b “Heads Up” study show that a greater proportion of subjects treated with AbbVie’s Rinvoq (upadacitinib 30mg, once daily) achieved at least a 75 percent improvement in the Eczema Area Severity Index (EASI 75) at week 16, compared to dupilumab (30
- Hoth Therapeutics Gets Greenlight to Start Phase 1b Trial of BioLexa for AD in Australiahttps://practicaldermatology.com/news/hoth-therapeutics-gets-greenlight-to-start-phase-1b-trial-of-biolexa-for-ad-in-australia/2460627/Hoth Therapeutics, Inc. received Human Research Ethics Committee clearance to commence the first cohort of the Phase 1b clinical trial of